Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore

USFDA inspection of Shilpa Medicare Unit VI at Bengaluru

The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature

Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate

GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally

Lyka’s patent pending Drug Pregabalin Gel 8% w/w receives approval from CDSCO

Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w

SIBUR to provide raw materials to Russian medical industry

SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization

Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals

Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic

Lupin acquires nine brands of Medical Nutritional Institute in South Africa

MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome

Clariant to launch eight new high-performing excipients at the CPHI Milan 2024

Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines

Briefs: Lupin, Alembic Pharmaceuticals and Piramal Pharma

Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations

Biocon partners with Tabuk to commercialize its Glucagon-like peptide-1 products in the Middle East